Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Everyday Seasonal Positions That Compensate Fairly in the US - 2Manual for Tracking down the Immaculate Magnificence of Focal Asia
- 3Which European countries have mandatory or voluntary military service
- 4A mom stopped giving her kids snacks — and sparked a debate about eating habits
- 5Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- Flourishing in Retirement: Individual Accounts of Post-Vocation Satisfaction
- Gauging the Upsides and downsides of Visas: A Complete Aide
- Ocean side Locations for a Family Excursion
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- Rick Steves Recommends This German Town's Castle Hotel With Rhine River Views
- Germany expresses 'great concern' over Israel's new death penalty law
- Manual for Picking the Ideal Wine Matching
- Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
- See the famous winged horse Pegasus fly in the autumn night sky
